Table 1 Baseline characteristics of study subjects
Budesonide/formoterol maintenance and reliever therapy vs. higher maintenance dose ICS + SABA | ||||||
|---|---|---|---|---|---|---|
Step 2 | Step 3 | Step 4 | ||||
Higher maintenance ICS + SABA (N = 262) | BUD/FORM maintenance and reliever therapy (N = 231) | Higher maintenance ICS + SABA (N = 1013) | BUD/FORM maintenance and reliever therapy (N = 1051) | Higher maintenance ICS + SABA (N = 769) | BUD/FORM maintenance and reliever therapy (N = 747) | |
Male, n (%) | 123 (47) | 104 (45) | 399 (39) | 433 (41) | 318 (41) | 315 (42) |
Age, mean | 30.6 | 32.2 | 39.5 | 37.5 | 42.6 | 42.0 |
ICS, n (%) Low | 262 (100) | 231 (100) | 242 (24) | 226 (22) | 0 | 0 |
Medium | 0 | 0 | 664 (66) | 711 (68) | 643 (84) | 591 (79) |
High | 0 | 0 | 107 (11) | 114 (11) | 126 (16) | 156 (21) |
LABA use, n (%) | 0 | 0 | 221 (22) | 214 (20) | 706 (92) | 689 (92) |
Asthma diagnosis, median years | 6.5 | 9 | 10 | 9 | 10 | 9 |
FEV1, % PN | 74.3 | 74.5 | 72.5 | 72.8 | 71.2 | 72.3 |
As-needed use, mean daily | 2.16 | 2.24 | 2.03 | 2.08 | 2.26 | 2.12 |
Symptom score, mean total | 1.36 | 1.37 | 1.57 | 1.63 | 1.74 | 1.65 |
Budesonide/formoterol maintenance and reliever therapy vs. same maintenance dose ICS/LABA + SABA | ||||||
Step 2 | Step 3 | Step 4 | ||||
Same maintenance ICS/LABA + SABA (N = 375) | BUD/FORM maintenance and reliever therapy (N = 389) | Same maintenance ICS/LABA + SABA (N = 896) | BUD/FORM maintenance and reliever therapy (N = 883) | Same maintenance ICS/LABA + SABA (N = 596) | BUD/FORM maintenance and reliever therapy (N = 597) | |
Male, n (%) | 157 (42) | 170 (44) | 389 (43) | 391 (44) | 274 (46) | 250 (42) |
Age, mean | 35.3 | 34.7 | 39.4 | 37.7 | 42.6 | 43.4 |
ICS, n (%) Low | 375 (100) | 389 (100) | 130 (15) | 136 (15) | 0 | 0 |
Medium | 0 | 0 | 671 (75) | 644 (73) | 415 (70) | 411 (69) |
High | 0 | 0 | 95 (11) | 103 (12) | 181 (30) | 186 (31) |
LABA use, n (%) | 0 | 0 | 107 (12) | 118 (13) | 548 (92) | 548 (92) |
Asthma diagnosis, median years | 8 | 9 | 11 | 10 | 12 | 13 |
FEV1, % PN | 72.5 | 73.7 | 71.9 | 72.1 | 70.8 | 70.3 |
As-needed use, mean daily | 2.01 | 1.98 | 2.17 | 2.18 | 2.34 | 2.23 |
Symptom score, mean total | 1.62 | 1.56 | 1.68 | 1.65 | 1.78 | 1.76 |
Budesonide/formoterol maintenance and reliever therapy vs. higher maintenance dose ICS/LABA + SABA | ||||||
Step 3* | Step 4 | |||||
Higher maintenance ICS/LABA + SABA (N = 1786) | BUD/FORM maintenance and reliever therapy (N = 1203) | Higher maintenance ICS/LABA + SABA (N = 1585) | BUD/FORM maintenance and reliever therapy (N = 1051) | |||
Male, n (%) | 716 (40) | 498 (41) | 654 (41) | 420 (40) | ||
Age, mean | 36.2 | 36.3 | 40.9 | 41.7 | ||
ICS, n (%) Low | 124 (7) | 139 (12) | 0 | 0 | ||
Medium | 1424 (80) | 918 (76) | 1283 (81) | 876 (83) | ||
High | 238 (13) | 146 (12) | 302 (19) | 175 (17) | ||
LABA use, n (%) | 119 (7) | 138 (11) | 1527 (96) | 1004 (96) | ||
Asthma diagnosis, median years | 11 | 11 | 10 | 12 | ||
FEV1, % PN | 72.7 | 71.9 | 71.4 | 70.4 | ||
As-needed use, mean daily | 2.28 | 2.26 | 2.34 | 2.27 | ||
Symptom score, mean total | 1.95 | 1.91 | 1.88 | 1.88 | ||